Led · Series D · Jul 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies built around a proprietary Lead-212 platform that combines secure isotope supply, automated manufacturing and scalable production. Its lead program, ADVC001, is a Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer that has shown encouraging Phase 1b anti-tumor activity and favorable tolerability and is currently in Phase 2 clinical development. The company emphasizes vertical integration — spanning isotope supply, advanced manufacturing and clinical development — to address supply and manufacturing constraints for targeted alpha therapies. With integrated operations across North America and Australia, AdvanCell plans to expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand. The recent US $315 million Series D financing is intended to advance ADVC001 toward registrational development and accelerate the company’s growing pipeline of targeted alpha therapies.

Led · Series F · Apr 2026

Calyxo develops the CVAC System, an all-in-one aspiration-based platform that uses irrigation and vacuum aspiration to continuously clear kidney stone fragments during and after laser lithotripsy. The CVAC System was FDA-cleared in 2024 and aims to enable more complete stone clearance, which the company says drives improved clinical outcomes. Clinical, preclinical, and health economic evidence cited by Calyxo report low residual stone volume, improved procedural efficiency, and reductions in downstream healthcare utilization and cost. The company announced that over 40,000 patients have been treated with the CVAC System, signaling growing physician adoption. Calyxo plans to use newly raised capital to expand commercial infrastructure, generate further clinical and health-economic evidence through ongoing and future studies, and continue product innovation. The company describes itself as focused on paradigm-shifting solutions to improve kidney stone care.

Participated · Convertible Note · Mar 2026

Imperative Care is a commercial-stage medical technology company focused on advancing treatments for thromboembolic disease, including ischemic stroke and other vascular diseases caused by blood clots. Its commercially available product portfolio includes the Zoom Stroke System, the Symphony Thrombectomy System, and the Prodigy Thrombectomy System, which have been used in more than 78,000 procedures. The company is also developing the Telos endovascular robotic platform, currently in development and not approved for sale. Imperative Care said the $100 million convertible note financing will support commercialization of its existing stroke and vascular portfolios, next‑generation product development, and clinical evidence generation. The company is based in Campbell, Calif., and announced a new board appointment tied to the financing.

Led · Series B · Dec 2025

Biobeat Technologies, Ltd. has created a disposable, patch-based ambulatory blood pressure monitoring (ABPM) system that collects continuous, 24-hour blood-pressure data without the discomfort of traditional cuff inflation cycles. The sensor allows patients to conduct normal daily activities and sleep undisturbed, after which a high-quality report is automatically uploaded to the institution’s electronic medical records. With operations in Tel Aviv and Boca Raton, the company is focused on making ABPM a standard of care for more than 100 million hypertensive patients in the United States. Biobeat’s solution is already FDA-cleared and positioned to replace cumbersome cuff-based devices that suffer from poor patient compliance. The firm plans to use its newly raised capital to build a field sales team and accelerate U.S. commercialization. Financially, Biobeat just secured a $50 million Series B round, adding to its resources for market expansion and product roll-out.

Participated · Equity · Nov 2025

Solve Therapeutics is a San Diego-based, clinical-stage biopharmaceutical company focused on creating best-in-class antibody-drug conjugates for solid tumor malignancies. Its proprietary CloakLink™ linker platform is engineered to lower ADC hydrophobicity, improve pharmacokinetics, enhance plasma stability, and reduce toxicity, thereby expanding the therapeutic index of ADCs. The lead assets, SLV-154 and SLV-324, are both in Phase 1 clinical trials and are paired with novel diagnostic tools to enable precision patient selection. Founded by executives behind VelosBio and Acerta Pharma, the company aims to integrate therapeutic and diagnostic development for a more personalized oncology approach. The new financing lifts the firm’s total capital raised to $321 million, following a $75 million round closed in December 2024. Proceeds will fund completion of Phase 1b studies for both lead programs and broaden operational capabilities as the pipeline advances toward later-stage trials.